Open AccessDaclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
Author(s) -
Lai Wei,
Fu Sheng Wang,
Ming Xiang Zhang,
Ji Dong Jia,
A. A. Yakovlev,
Wen Xie,
Eduard Burnevich,
Jun Niu,
Yong Jin Jung,
Xiang Jiang,
Min Xu,
Xin Yue Chen,
Qing Xie,
Jun Li,
Jin Hou,
Hong Tang,
Xiao Guang Dou,
Yash Gandhi,
HU Wen-bin,
Fiona McPhee,
Stephanie Noviello,
Michelle Treitel,
Ling Mo,
Jun Deng
Publication year - 2018
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v24.i12.1361
Subject(s) - daclatasvir , medicine , placebo , gastroenterology , ribavirin , clinical endpoint , hepatitis c virus , hepatitis c , randomized controlled trial , immunology , virus , pathology , alternative medicine
To assess daclatasvir plus asunaprevir (DUAL) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection.